---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015524"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:30:17.847198+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA signs master clinical supply agreement with Roche for ateganosine-atezolizumab combo studies

## Summary
- Agreement supports future studies combining MAIA's ateganosine (THIO) with Roche's atezolizumab (Tecentriq) for multiple hard-to-treat cancers.
- Preclinical data showed ateganosine highly synergistic and effective with anti-PD-L1 agent atezolizumab.
- Ateganosine is a first-in-class telomere-targeting agent in clinical development for NSCLC after checkpoint inhibitor progression.
- CEO Vlad Vitoc said partnership with Roche strengthens mission to find safe and effective cancer treatments.

## SEC filing metadata
- accession: 0001641172-25-015524
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225015524/0001641172-25-015524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225015524/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015524
- JSON: https://secwatch.observer/filing/0001641172-25-015524.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.